As biopharma and healthcare companies face a rapidly shifting regulatory environment, marketing and advisory firm Avalere ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

Fosun Pharma is spending 1.4 billion Chinese yuan ($200 million) to take on a 53% stake in Green Valley Pharmaceuticals and ...

The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

A new survey from SiriusXM Media details the issues that many people have with the current state of TV drug ads—and ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given ...